Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Supreme Court Ruling Allows Patent Challenge

January 15, 2007 | A version of this story appeared in Volume 85, Issue 3

The Supreme Court has issued a ruling making it less risky for companies to challenge the validity of patents held by other companies. By an 8 to 1 vote, the high court ruled that biotech firm MedImmune could resume its challenge of a patent even though it was abiding by a licensing agreement with Genentech, the patent's holder. The Jan. 9 decision reverses a previous ruling by the U.S. Court of Appeals for the Federal Circuit—the court that hears all patent appeals—requiring companies to breach licensing agreements before they can sue to have the patent declared invalid. This change means that companies do not have to risk being sued by the patent holder for infringement of licensing agreements in order to have the courts assess a patent. Although the ruling will help smaller companies that can't afford to challenge patents held by larger companies because of the potential of an infringement suit, some legal experts worry that this ruling will destabilize existing patent agreements. The case between MedImmune and Genentech now goes back to lower courts to decide whether the questioned patent should be upheld or thrown out.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.